Status:
COMPLETED
Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Congenital Bleeding Disorder
Haemophilia A
Eligibility:
MALE
Brief Summary
This study is conducted in Europe and Asia. The aim of this observational study is to monitor antibody formation towards the room temperature stable formulation of NovoSeven® (activated recombinant hu...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Diagnosed with congenital haemophilia A or B with inhibitors to factor VIII or factor IX
- Treated with room temperature stable NovoSeven®
Exclusion
Key Trial Info
Start Date :
November 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2015
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT01220141
Start Date
November 1 2010
End Date
March 1 2015
Last Update
April 16 2015
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Prov. de Buenos Aires, Argentina, B1636DSU
2
Vienna, Austria, A-1010
3
Brussels, Belgium, 1070
4
Paris La Défense Cedex, France, 92932